Decision analysis to evaluate lymphangiography in the management of patients with Hodgkin's disease.
We used decision analysis to explore the role of lymphangiography for staging Hodgkin's disease. Factors included were status of the patient before the test, accuracy and mortality of lymphangiography, mortality of laparotomy and effectiveness of selected treatment. We analyzed hypothetical cases with varying probabilities being in Stages I+II, III and IV to determine the population in which indication for laparotomy would depend upon results of lymphangiography. Calculations made for asymptomatic patients revealed that the diagnostic usefulness of lymphangiography is restricted to patients either with a relatively low probability of Stage IV or with a very high probability of Stage IV disease. This population is further restricted as false-positive and false-negative results of lymphangiography increase.
D000970:Antineoplastic Agents / Q000008:administration & dosage; D003657:Decision Making; D004359:Drug Therapy, Combination; D006689:Hodgkin Disease / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000532:radiotherapy; D006801:Humans; D007813:Laparotomy / Q000401:mortality; D008220:Lymphography / Q000401:mortality; D011336:Probability; D012075:Remission, Spontaneous; D012306:Risk
D000970:Antineoplastic Agents